Self-inactivating retroviral vectors with improved RNA processing

Gene Therapy

Volumn 11, Issue 21, 2004, Pages 1568-1578

  Kraunus, J ^a,b,c   Schaumann, D H S ^a,d   Meyer, J ^c   Modlich, U ^c   Fehse, B ^b   Brandenburg, G ^d   von Laer, D ^d   Klump, H ^c   Schambach, A ^c   Bohne, J ^c   Baum, C ^c,e  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Georg Speyer Haus ^*  (Germany)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Hematopoiesis; Mouse leukemia virus; Vector safety

Indexed keywords

RETROVIRUS VECTOR;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CARCINOMA CELL; CELL TYPE; CONTROLLED STUDY; EMBRYONAL CARCINOMA; FIBROBLAST; GENE EXPRESSION; GENE INSERTION; HEMATOPOIETIC STEM CELL; HEPATITIS VIRUS; HUMAN; HUMAN CELL; INTRON; LONG TERMINAL REPEAT; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RETROVIRUS; RNA PROCESSING; RNA SPLICING; RNA TRANSLATION; SIGNAL TRANSDUCTION; START CODON; T LYMPHOCYTE; TRANSGENE; VIRUS INACTIVATION;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HEPATITIS B VIRUS, WOODCHUCK; HUMANS; LYMPHOCYTES; MICE; MICE, INBRED C57BL; RNA PROCESSING, POST-TRANSCRIPTIONAL; SAFETY; TRANSFECTION; TRANSGENES; VIRUS INACTIVATION;

MARMOTA MONAX; WOODCHUCK HEPATITIS B VIRUS;

EID: 7244231295     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302309     Document Type: Article

References (49)

1. Baum C et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003; 101: 2099-2114.
2. Thomas CE et al. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4: 346-358.
3. Hacein-Bey-Abina S et al. LMO-2 associated clonal lymphoproliferations in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
4. Kohn D et al. American society of gene therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther 2003; 8: 180-187.
5. Kohn DB et al. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003; 3: 477-488.
6. Yu SF et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986; 83: 3194-3198.
7. Hildinger M et al. Design of 5′ untranslated sequences in retroviral vectors developed for medical use. J Virol 1999; 73: 4083-4089.
8. Kim SH et al. Construction of retroviral vectors with improved safety, gene expression, and versatility. J Virol 1998; 72: 994-1004.
9. Schambach A et al. Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol Ther 2000; 2: 435-445.
10. Fong YW, Zhou Q. Stimulatory effect of splicing factors on transcriptional elongation. Nature 2001; 414: 929-933.
11. Reed R, Hurt E. A conserved mRNA export machinery coupled to pre-mRNA splicing. Cell 2002; 108: 523-531.
12. Hammerskjold ML. Constitutive transport element-mediated nuclear export. Curr Top Microbiol Immunol 2001; 259: 77-93.
13. Wodrich H et al. A new RNA element located in the coding region of a murine endogenous retrovirus can functionally replace the rev/rev-responsive element system in human immunodeficiency virus type 1 gag expression. J Virol 2001; 75: 10670-10682.
14. Wodrich H, Krausslich HG. Nucleocytoplasmic RNA transport in retroviral replication. Results Probl Cell Differ 2001; 34: 197-217.
15. Trubetskoy AM et al. R region sequences in the long terminal repeat of a murine retrovirus specifically increase expression of unspliced RNAs. J Virol 1999; 73: 3477-3483.
16. Aiuti A et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-2413.
17. Hacein-Bey-Abina S et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185-1193.
18. Zufferey R et al. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73: 2886-2892.
19. Werner M et al. B cell-specific transgene expression using a self-inactivating retroviral vector with human CD19 promoter and viral posttranscriptional regulatory element. Gene Therapy 2004; 11: 992-1000.
20. Popa I et al. CRM1-dependent function of a cis- cting RNA export element. Mol Cell Biol 2002; 22: 2057-2067.
21. Baum C et al. Novel retroviral vectors for efficient expression of the multidrug-resistance (mdr-1) gene in early hemopoietic cells. J Virol 1995; 69: 7541-7547.
22. Baum C et al. Retroviral vector-mediated gene expression in hematopoietic cells. Curr Opin Mol Ther 1999; 1 605-612.
23. Grez M et al. Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells. Proc Natl Acad Sci USA 1990; 87: 9202-9206.
24. Wahlers A et al. Influence of multiplicity of infection and protein stability on retroviral vector-mediated gene expression in hematopoietic cells. Gene Therapy 2001; 8: 477-486.
25. Kustikova O et al. Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 2003; 110: 2099-2104.
26. Challita PM et al. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol 1995; 69: 748-755.
27. Li KJ, Garoff H. Packaging of intron-containing genes into retrovirus vectors by alphavirus vectors. Proc Natl Acad Sci USA 1998; 95: 3650-3654.
28. Engels B et al. Retroviral vectors for high transgene expression in T lymphocytes. Hum Gene Ther 2003; 14: 1155-1168.
29. Knipper R et al. Improved post-transcriptional processing of an MDR1 retrovirus elevates expression of multidrug resistance in primary human hematopoietic cells. Gene Therapy 2001; 8: 239-246.
30. Schiedlmeier B et al. High-level ectopic hoxb4 expression confers a profound in vivo competitive growth advantage on human cord blood cd34+ cells, but impairs lymphomyeloid differentiation. Blood 2003; 101: 1759-1768.
31. Egelhofer M et al. Inhibition of HIV-1 entry in cells expressing gp41-derived peptides. J Virol 2004; 78: 568-575.
32. Wahlers A et al. In vivo analysis of retroviral enhancer mutations in hematopoietic cells: SP1/EGR1 and ETS/GATA motifs contribute to long terminal repeat specificity. J Virol 2002; 76 303-312.
33. Baum C et al. The potent enhancer activity of SFFVp in hematopoietic cells is governed by a binding site for sp1 in the upstream control region and by a unique enhancer core creating an exclusive target for PEBP/CBF. J Virol 1997; 71: 6323-6331.
34. Sun W et al. Transactivation of the Moloney murine leukemia virus and T-cell receptor beta-chain enhancers by CBF and ETS requires intact binding sites for both proteins. J Virol 1995; 69: 4941-4949.
35. Hamaguchi I et al. Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro. J Virol 2000; 74: 10778-10784.
36. Lois C et al. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002; 295: 868-872.
37. Pfeifer A et al. Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc Natl Acad Sci USA 2002; 99: 2140-2145.
38. Stewart CL et al. Expression of retroviral vectors in transgenic mice obtained by embryo infection. EMBO J 1987; 6: 383-388.
39. Ramezani A et al. Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood 2003; 101: 4717-4724.
40. Ailles LE, Naldini L. HIV-1-derived lentiviral vectors. Curr Top Microbiol Immunol 2002; 261: 31-52.
41. Wagner R et al. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum Gene Ther 2000; 11: 2403-2413.
42. Emerman M, Temin HM. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 1984; 39: 449-467.
43. Zaiss AK et al. RNA 3′ readthrough of oncoretrovirus and lentivirus: Implications for vector safety and efficacy. J Virol 2002; 76: 7209-7219.
44. Akagi K et al. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res 2004; 32: D523-D527.
45. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 1996; 7 1405-1413.
46. Morita S et al. Plat-e: an efficient and stable system for transient packaging of retroviruses. Gene Therapy 2000; 7 1063-1070.
47. Fehse B et al. A novel 'sort-suicide' fusion gene vector for t cell manipulation. Gene Therapy 2002; 9: 1633-1638.
48. Li Z et al. Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose. Exp Hematol 2003; 31: 1206-1214.
49. Ayuk F et al. Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements. Gene Therapy 1999; 6: 1788-1792.